About the study

This study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of IGM-8444 as a single agent and in combination in subjects with relapsed and/or refractory solid or hematologic cancers, as well as newly diagnosed cancers, and an open-label, randomized study of IGM-8444+FOLFIRI (± bevacizumab).

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

1. Age ≥ 18 years at time of signing ICF
2. ECOG Performance Status of 0 or 1
3. Histologic documentation of incurable, locally advanced or metastatic tumor of the type being evaluated in individual cohorts.
4. Adequate hepatic and renal function and adequate bone marrow reserve function.
5. For combination cohorts, patients must be eligible to receive the chemotherapy or targeted agent.
6. Ph1a only: No more than three prior therapeutic regimens.
7. Ph1b only: Must be FOLFIRI naive subjects and must have received only 1 prior therapeutic regimen administered for the treatment of cancer in the advanced/metastatic setting. Key

Exclusion criteria

1. Inability to comply with study and follow-up procedures.
2. Prior DR5 agonist therapy.
3. Concomitant use of agents well-known to cause liver toxicity.
4. Concomitant use of anti-cancer agents
5. Palliative radiation to bone metastases within 2 weeks prior to Day 1.
6. Major surgical procedure within 4 weeks prior to Day 1.
7. Untreated or active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control). Patients with a history of treated CNS metastases are eligible.
8. Prior use of any chemotherapeutic agent or small molecule inhibitors (SMI) within 2 weeks or 5 half-lives, prior to the first dose of study treatment
9. Treatment with a monoclonal antibody, or any other anticancer agent (including biologic, experimental, or hormonal therapy) investigational or otherwise, that is not chemotherapy or a SMI, within 4 weeks or five half-lives prior to first dose of study treatment.
10. Ph1b: Subjects who have previously received FOLFIRI treatment for advanced or metastatic disease

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.